Mucosal IgA responses in influenza virus infections; thoughts for vaccine design

The current challenge in influenza vaccine design is to induce long-lasting protection not only against the vaccine strain, but also against drifted (point mutations in the surface antigens HA or NA) and even shifted (exchange of genome segments) strains. Several immune mediators that can induce cro...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 30; no. 40; pp. 5893 - 5900
Main Authors van Riet, Elly, Ainai, Akira, Suzuki, Tadaki, Hasegawa, Hideki
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 31.08.2012
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The current challenge in influenza vaccine design is to induce long-lasting protection not only against the vaccine strain, but also against drifted (point mutations in the surface antigens HA or NA) and even shifted (exchange of genome segments) strains. Several immune mediators that can induce cross-protection have been described, such as CD4 T-cells, CD8 T-cells and antibodies, including IgA. However, most vaccines are now administered intramuscularly or subcutaneously and subsequently relatively little is known on the role of local, mucosal responses. Since local IgA responses have been shown to play an important role in responses to natural infection, and IgA responses in mice were shown to also be involved in cross-protection, the research on mucosal influenza vaccines is currently expanding. However, the functioning of the mucosal immune system, especially in the respiratory tract, is just beginning to be revealed. Here, the current knowledge on the induction of IgA, the role of influenza specific IgA producing B-cells in anti-influenza immunity as well as the role of humoral memory responses induced upon vaccination will be reviewed.
Bibliography:http://dx.doi.org/10.1016/j.vaccine.2012.04.109
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2012.04.109